Hemopericardium in a patient treated with dabigatran etexilate

Pharmacotherapy

Volumn 32, Issue 5, 2012, Pages

  Barton, Cassie A ^a   Mcmillian, Wesley D ^a,d   Raza, S Sadi ^b   Keller, Ray E ^c,d  

^a Department of Pharmacy ^*  (United States)

^b Division of Cardiology   (United States)

^c Department of Surgery   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

Dabigatran; Dilute thrombin time; Hemopericardium; Pericardial effusion

Indexed keywords

DABIGATRAN ETEXILATE; DRONEDARONE; HEMOGLOBIN; RHEUMATOID FACTOR; TROPONIN;

ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HEART ATRIUM FIBRILLATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEMOPERICARDIUM; HUMAN; INCIDENTAL FINDING; LEUKOCYTE COUNT; MALE; PARTIAL THROMBOPLASTIN TIME; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THORAX PAIN; THROMBOCYTE COUNT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; HUMANS; MALE; PERICARDIAL EFFUSION; PYRIDINES; THROMBIN TIME;

EID: 84864350306     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01036.x     Document Type: Article

References (14)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995;155:468-73.
2. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran etexilate) package insert. Ridgefield, CT: Author; 2011.
3. Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). Heart Rhythm 2011;8: e1-8.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
5. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
6. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
7. Stables RH, Campbell S, Ormerod OJM. Haemopericardium in rheumatoid arthritis. Int J Cardiol 1989;23:268-70.
8. Braiteh F, Plana JC. Spontaneous haemopericardium with subacute cardiac tamponade in a patient with lung cancer receiving Coumadin. QJM 2009;102:575.
9. Griffiths Ap, Beddall A, Pegler S. Fatal haemopericardium and gastrointestinal hemorrhage due to possible interaction of cranberry juice with warfarin. J R Soc Promot Health 2008;128:324-6.
10. Hillyard RF. Delayed clinical presentation of hemorrhagic pericardial effusion in a patient receiving warfarin sodium. Am J Orthop 2007;36:E144-7.
11. Hong YC, Cheng YG, Hsiao CT, Kuan JT, Chiu TF, Chen JC. Cardiac tamponade secondary to haemopericardium in a patient on warfarin. Emerg Med J 2007;24:679-80.
12. Su HM, Voon WC, Chu CS, Lin TH, Lai WT, Sheu SH. Heparin-induced cardiac tamponade and life-Threatening hyperkalemia in a patient with chronic hemodialysis. Kaohsiung J Med Sci 2005;21:128-33.
13. Mohammad S, Austin SM. Hemopericardium with cardiac tamponade after intravenous thrombolysis for acute myocardial infarction. Clin Cardiol 1996;19:432-4.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.